EG30 for the treatment of Alzheimer's disease

EG-30: clinical phase drug for AMD and Glaucoma

EG-30 – the highlights:

· Excellent safety profile in healthy volunteers and glaucoma patients

•Low systemic exposure

•No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)

·Extensive safety and efficacy preclinical package:

•EG-30 inhibit the formation of amyloid beta oligomers and serve as a cytoprotectant agent

•Efficacy in dry AMD and glaucoma animal models

•Safety and toxicology including 6 months toxicology studies in rabbits and monkeys

·An FDA approved development path allowing a single confirmatory study for FDA approval of EG-30 for both glaucoma and dry AMD

·New derivatives for Alzheimer treatment

Project manager

Elisha Natan
Director BD

Project researchers

Ehud Gazit
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology